Underuse of appropriate health care is harmful and costly – STAT

T

he phrase less is more has become omnipresent in health care. Whether its inserting too many artery-opening stents into people with angina, performing too many surgeries for back pain, ordering too many CT scans for headaches, or prescribing too many narcotics for people with chronic pain, overuse is rampant in our medical system. As the Senate tries to fashion a bill that will likely end up taking away access to health care from millions of Americans, it is important to remember that underuse of evidence-based services is an equally pressing issue. When it comes to health, less is sometimes lesser.

While the United States outspends every other developed nation on health care nearly 18 percent of our gross domestic product Americans lag behind many other countries in the quality of care they receive at the beginning, middle, and end of their lives. This discordance has increased pressure to reduce costs, and so-called medical waste has become a prominent target. While several measures have been developed to curb wastefulness, some of these have had the unintended consequence of reducing access to potentially lifesaving treatments or therapies.

In cardiology, my specialty, the overuse of artery-opening stents has gained substantial attention. While absolutely lifesaving when used for someone in the throes of a heart attack, stents are no better than medication for improving outcomes for patients who have the stable chest pain known as angina. To set standards for stent placement, professional cardiology societies have introduced appropriateness criteria that offer guidelines as to when, and when not, to place a stent.

advertisement

Many states now also require public reporting of patient outcomes after stent placement. While this reporting has helped reduce unnecessary use of stents, it has also led to their underuse in the sickest patients, presumably because physicians did not want to have poorer outcomes and death which would be expected in this population count against them.

A similar story has evolved in the world of health insurance. In an effort to make consumers more cost-sensitive, insurers have increased copays associated with medical charges. This strategy has had some benefits. A significant part in the slowdown of heath care costs is related to patients having more skin in the game, Dr. Mark McClellan, a former head of the Food and Drug Administration and the Centers for Medicare and Medicaid Services, and now the director of the Margolis Center for Health Policy at Duke University, told me.

However, a clinical trial involving about 6,000 individuals who had just suffered heart attacks showed that those who had no copays associated with their medications had lower rates of future strokes, heart attacks, and other cardiovascular complications, and incurred no increased cost to insurers, compared to those with standard copays. A significant increase in complications among those with copays was driven primarily by fewer patients taking their prescribed medications. African-Americans are especially prone to underusing medications due to cost. In other words, well-meaning policies meant to curb excess can limit access.

Medical interventions aimed at preventing disease or keeping it from escalating are universally underused compared to those with shorter-term effects. Consider people with asthma. Its recommended that they use a daily controller inhaler to ease the airway inflammation at the root of the disease, as well as a rescue inhaler that provides only short-term relief when symptoms appear. Yet controller inhalers are widely underused while many individuals with asthma overdose on rescue inhalers.

This is true with regard to heart disease as well: Even as the use of cardiac imaging and cardiac procedures are skyrocketing, inexpensive medications proven to prevent future heart attacks and strokes are inconsistently prescribed or taken. A similar trend is observed in immunization and screening tests.

The low uptake of appropriate medical services can actually lead to downstream overuse. African-Americans, Hispanics, and other minorities are more likely to undergo procedures and surgeries at the end of life and incur significantly more costs in the last six months of life than whites. Much of this is driven by an underuse of preventive measures in the years preceding the end.

According to the Dartmouth Atlas of Health Care, which has been exploring variations in the use and distribution of medical resources in the United States for the past 20 years, spending decreases when recommended care is practiced.

Too much medicine has been the source of unbridled indignation over the past few years. Curiously, theres been little outcry about the underuse of evidence-based care. Perhaps this differential reaction stems from the incorrect notion that overuse is associated with rising medical costs while underuse of evidence-based care isnt. Thats simply not true.

Many studies that have evaluated the number of patients who rightly received specific services did not analyze how many did not get them. So rather than looking at overuse and underuse, perhaps we need to focus on appropriate care, or what the Lown Institute, a Boston-based nonprofit think tank, refers to as RightCare, which melds these two seemingly opposite trends.

A movement toward performance-based payments may increase the use of appropriate care by physicians and health systems. All services are vulnerable to over- and under-utilization, Dr. Harlan Krumholz, a cardiologist and professor at Yale University, wrote to me in an email, and the challenge for the future is to provide the information that helps patients make the best choices. A stent, for example, can be the most and least appropriate intervention for a patient, given the clinical context. Patients need to be more engaged in their health care and their physicians need to balance medical treatments that are less likely to provide instant relief with those that reduce the risk of serious events over the long term.

Over the past decade, some health care experts have skeptically asked the question, Is more care better? Policymakers mulling the Senate health care bill must keep in mind that, when the care is truly appropriate, more is indeed better.

Haider Warraich, M.D., is a fellow in cardiology at Duke University Medical Center and the Duke Clinical Research Institute, and author of Modern Death: How Medicine Changed the End of Life (St. Martins Press).

Haider Warraich can be reached at haider.warraich@duke.edu Follow Haider on Twitter @haiderwarraich

Trending

A civil war over painkillers rips apart the medical

A civil war over painkillers rips apart the medical community and leaves patients in fear

Giving newborns medicine is a dangerous guessing game. Can

Giving newborns medicine is a dangerous guessing game. Can we make it safer?

With ads, rare for a medical device maker, Boston

With ads, rare for a medical device maker, Boston Scientific shifts gears

Recommended

Medical debt? Big changes are coming to the way

Medical debt? Big changes are coming to the way credit agencies report it

Meet the doctor who helped inspire a controversial Netflix

Meet the doctor who helped inspire a controversial Netflix movie about anorexia

Updating drug labels would greatly help patients but

Updating drug labels would greatly help patients but few companies do it

Read this article:

Underuse of appropriate health care is harmful and costly - STAT

Precision Medicine: Integration May Be Closer Than You Think – HealthLeaders Media

Precision medicine is, ironically, an imprecise term.

As it is often used today, the phrase suggests that precision is novel to the practice of medicine, and to many, it means incorporating sophisticated genetic testing into its practice.

The term can even suggest that there are now possibilities of miracle cures that were never possible before.

Sometimes healthcare organizations encourage that attitude through their marketing and advertising, but to a degree, that kind of thinking more represents hype than substance.

And while genetic testing and the information it can provide can help better tailor treatment options for individual patients, especially in cancer care, experts say healthcare executives and clinicians must be careful not to encourage false hope among vulnerable patients and their families.

Yet in a time of rapid evolution of more precise and tailored treatment options, executives and clinicians are charged with divining the difficult calculus between the possible and the practical in their precision medicine organizational structure and service offerings.

In reality, precision has always been the goal of physicians as medicine has evolved over the past couple of hundred years, says Robert Mennel, MD, director of the Baylor Precision Medicine Institute in Dallas.

"In some areas we're there. We have well-accepted tests for certain diseases that, if you're not using them, I would consider to be malpractice in many situations," he says.

However, even top-level academic medicine is still quite far away from being able to look at an individual's whole genome and predict a therapy for every disease.

"But the promise of precision medicine is there, and medicine 10 years from now is going to be quite different than it is now," he says.

One area where genetic testing is ready for prime time is in noninvasive prenatal testing, says Scott A. Beck, administrator of the Center for Individualized Medicine at the Mayo Clinic in Rochester, Minn.

Go here to read the rest:

Precision Medicine: Integration May Be Closer Than You Think - HealthLeaders Media

‘Fusion genes’ drive formation and growth of colorectal cancer – Medical Xpress

July 12, 2017 by George Lowery Mouse intestinal organoids that scientists genetically engineered to study colon cancer. Using gene editing technology, the investigators fused together the genes Ptprk and Rspo3 to determine their effect on cancer development. Credit: Cornell University

Genetic mutations caused by rearranged chromosomes drive the development and growth of certain colorectal cancers, according to new research conducted by Weill Cornell Medicine investigators.

Many of the genetic mutations present in colorectal cancer have been known for decades. But their exact role in cancer's development and progression has not been clear. "We knew that these mutations existed, but not whether they contribute to the disease," said Lukas Dow, an assistant professor of biochemistry in medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. "So we are interested in whether they are actually driving cancer and whether they can potentially be targets for drugs that treat it."

In a paper published July 11 in Nature Communications, Dow and his colleagues describe how large pieces of chromosomes are deleted or inverted, resulting in new, mutated so-called fusion genes created from parts of two other genes that are responsible for the formation of some colon cancers.

The researchers used the gene editing technology CRISPR, which allows scientists to easily alter any piece of DNA in an organism, to cut the DNA in normal human intestinal cells and create fusion genes. In this way, they engineered the genetic mutations in two genes Rspo2 and Rspo3 known to be associated with colorectal cancer. They then created mice containing these genes to study the genes' effect on colon cancer development.

Though CRISPR has received a lot of attention in the last several years, this is the first time the tool has been used this way. "We created the first CRISPR-based transgenic animal model for inducing large-scale chromosomal rearrangements," Dow said.

These chromosomal rearrangements in the Rspo genes did in fact initiate growth of colon cancer in the mice. The mice containing the engineered genes developed multiple precancerous tumors that are the precursors to colorectal cancer. "This is the first evidence that these specific fusions can drive tumor development," Dow said.

Dow's team went on to treat the mice that developed cancer with an experimental drug, LGK974, which blocks a protein necessary for Rspo fusion genes to cause disease. "The tumors shrank and the mice were fine as long as they continued to take LGK974," Dow said. In addition, the drug only suppressed growth of the cancer cells; it had no obvious negative effect on healthy cells in the mouse intestine.

The study's results hold particular promise for the treatment of colorectal cancer in humans, Dow said. This form of cancer has historically been a difficult disease to treat. Chemotherapy drugs have limited impact against colorectal cancer and developing targeted therapies drugs that target aspects of cancer cells that make them different from healthy cells has proven difficult. "Our results give us confidence that if we can deliver LGK974 effectively to patients with these fusion genes," Dow said, "then we should be able to see some tumor response with these targeted agents."

Explore further: Novel gene editing approach to cancer treatment shows promise in mice

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Visit link:

'Fusion genes' drive formation and growth of colorectal cancer - Medical Xpress

Program examines genes, disease – Waupaca County News

July 12, 2017

Scott Hebbring will discuss the impact of genetics on medicine at 6:30 p.m. Monday, July 17, at the Waupaca Area Public Library.

Sponsored by Winchester Academy, the program is the second in a two-part series.

A research scientist at the Marshfield Clinic, Hebbring will focus on how genetic information and electronic medical record data are revolutionizing health care.

He will discuss his research that shows how family and genetic data may be used to predict, prevent and treat human disease.

Hebbring completed his bachelors degree at the University of Wisconsin-Eau Claire and his doctoral degree in biochemistry and molecular biology at the Mayo Clinic Graduate School in Rochester, Minnesota.

At the Mayo Clinic, his research included the study of genes and enzymes involved in folate metabolism, pharmacogenomics and prostate cancer.

This program is free and open to the public.

Winchester Academy is funded through sponsors and tax-deductible donations. Karen and John Hebbring are the sponsors of Dr. Hebbrings program.

For more information about Winchester Academy, check winchesteracademywaupaca.org, follow on Facebook or contact Executive Director Ann Buerger Linden at 715-258-2927 or buergerlinden@gmail.com.

Original post:

Program examines genes, disease - Waupaca County News

‘Fusion genes’ drive formation and growth of colorectal cancer … – Cornell Chronicle

Teng Han

Mouse intestinal organoids that scientists genetically engineered to study colon cancer. Using gene editing technology, the investigators fused together the genes Ptprk and Rspo3 to determine their effect on cancer development.

Genetic mutations caused by rearranged chromosomes drive the development and growth of certain colorectal cancers, according to new research conducted by Weill Cornell Medicine investigators.

Many of the genetic mutations present in colorectal cancer have been known for decades. But their exact role in cancers development and progression has not been clear. We knew that these mutations existed, but not whether they contribute to the disease, said Lukas Dow, an assistant professor of biochemistry in medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. So we are interested in whether they are actually driving cancer and whether they can potentially be targets for drugs that treat it.

In a paper published July 11 in Nature Communications, Dow and his colleagues describe how large pieces of chromosomes are deleted or inverted, resulting in new, mutated so-called fusion genes created from parts of two other genes that are responsible for the formation of some colon cancers.

The researchers used the gene editing technology CRISPR, which allows scientists to easily alter any piece of DNA in an organism, to cut the DNA in normal human intestinal cells and create fusion genes. In this way, they engineered the genetic mutations in two genes Rspo2 and Rspo3 known to be associated with colorectal cancer. They then created mice containing these genes to study the genes effect on colon cancer development.

Though CRISPR has received a lot of attention in the last several years, this is the first time the tool has been used this way. We created the first CRISPR-based transgenic animal model for inducing large-scale chromosomal rearrangements, Dow said.

These chromosomal rearrangements in the Rspo genes did in fact initiate growth of colon cancer in the mice. The mice containing the engineered genes developed multiple precancerous tumors that are the precursors to colorectal cancer. This is the first evidence that these specific fusions can drive tumor development, Dow said.

Dows team went on to treat the mice that developed cancer with an experimental drug, LGK974, which blocks a protein necessary for Rspo fusion genes to cause disease. The tumors shrank and the mice were fine as long as they continued to take LGK974, Dow said. In addition, the drug only suppressed growth of the cancer cells; it had no obvious negative effect on healthy cells in the mouse intestine.

The studys results hold particular promise for the treatment of colorectal cancer in humans, Dow said. This form of cancer has historically been a difficult disease to treat. Chemotherapy drugs have limited impact against colorectal cancer and developing targeted therapies drugs that target aspects of cancer cells that make them different from healthy cells has proven difficult. Our results give us confidence that if we can deliver LGK974 effectively to patients with these fusion genes, Dow said, then we should be able to see some tumor response with these targeted agents.

Geri Clark is a freelance writer for Weill Cornell Medicine.

Link:

'Fusion genes' drive formation and growth of colorectal cancer ... - Cornell Chronicle

Genetically engineered salmon is coming to America – The Week Magazine

Sign Up for

Our free email newsletters

On a hill above the cold waters around Prince Edward Island, technicians painstakingly create fertilized Atlantic salmon eggs that include growth-enhancing DNA from two other fish species. The eggs will be shipped to tanks in the high rainforest of Panama, where they will produce fish that mature far more quickly than normal farmed salmon.

More than 20 years after first seeking approval from the U.S. Food and Drug Administration, AquaBounty Technologies of Maynard, Massachusetts, plans to bring these "AquAdvantage" fish to the U.S. and Canadian markets next year. And in the small town of Albany, Indiana, workers will soon begin converting a land-based aquaculture facility to produce about 1,300 U.S. tons of these salmon annually, in the first U.S. facility to generate GE animals for human consumption.

The company also plans to open a second aquaculture facility at Prince Edward Island if it can rise above its latest round of legal battles and persuade grocery stores and restaurants to snap up the genetically engineered fish. Before the FDA cleared the salmon for consumption in 2015, in its first approval of GE animal protein as human food, it received 1.8 million messages opposing these fish. Perhaps more substantively, many outside researchers remain concerned about AquaBounty's plans.

Safety and nutrition

Aquaculture specialists generally aren't skeptical about whether the fish will be healthy to eat, although that's one issue hinted at in a lawsuit multiple organizations, including Friends of the Earth, have filed against the FDA. Dana Perls, senior food and technology campaigner with Friends of the Earth in Berkeley, California, says the FDA didn't fully examine questions about eating the salmon initially raised by Health Canada, that country's public health department including susceptibility to disease and potential allergic reactions.

"This is a poorly studied, risky, and unlabeled genetically engineered fish," she says, adding that more than 80 U.S. grocery chains have committed not to buy it. However, Health Canada eventually concluded that fillets derived from AquAdvantage salmon "are as safe and nutritious as fillets from current available farmed Atlantic salmon," and approved the fish for consumption in 2016.

"There's no reason to suspect these fish from a food safety perspective," says Cyr Couturier, chair of aquaculture programs at Memorial University's Marine Institute in St. John's, Newfoundland. "They have no unnatural products that humans wouldn't otherwise consume."

Similar transgenic salmon created by a decades-long Fisheries and Oceans Canada research program tested well within normal salmon variations, adds Robert Devlin, engineering research scientist at the agency in North Vancouver, British Columbia. But critics do raise two other main concerns about AquaBounty's quest: the economic sustainability of the land-based approach, and the environmental risk to ecosystems if the fish escape.

Fish on land

AquaBounty will raise its GE fish in land-based recirculating aquaculture systems, known as RAS basically huge aquaria designed to minimize water use, maximize resources and accommodate high stocking densities. "While farming salmon in sea cages is less expensive and less technologically complex than a land-based farm," the company's website points out, "sea cages are susceptible to a number of hazards such as violent storms, predators, harmful algal blooms, jellyfish attacks, fish escapes, and the transmission of pathogens and parasites from wild fish populations."

Given the potential opportunity to achieve greater production control and avoid some of the environmental concerns of sea farms, many RAS projects have launched around the world in the past decade. However, most of these projects are small, and many have failed or are struggling.

The big problem is cost. RAS facilities need much more capital than ocean farms with similar production rates, and they're expensive to operate.

"Land-based systems use a lot of freshwater, even though it's recirculated, and a lot of electricity," notes Couturier. Such systems "operate at an economic disadvantage because much of their cost goes toward creating growing conditions occurring naturally within the ocean," summed up one 2014 report that found producing Atlantic salmon in Nova Scotia would not be economically feasible.

AquaBounty, which is buying its Indiana plant from a collapsed RAS venture, expects to beat these odds mainly because its GE salmon reach market size in about half the time of normal farmed salmon in 1618 months rather than 2836 months, the company says. Ravenous as they are, with their growth hormones continually wired on, the fish still require about a quarter less feed than normal fish. (Although farmed salmon are very efficient at converting food to flesh a pound of feed converts close to a pound of flesh feed remains a major expense.)

The company also says that salmon in its RAS facilities won't need vaccines or antibiotics because it will tightly control conditions. However, "they will have some disease issues of course, as will any animal that's reared in high densities," Couturier predicts.

If AquaBounty can compete on cost, there will be some justification for promoting its product as "the world's most sustainable salmon." In addition to requiring less feed, growing fish in Indiana or Prince Edward Island can slash the high carbon costs of flying fish from Norway or Chile, two leading suppliers of farmed salmon in the U.S.

Still, says Couturier, "I wish them all the best, but I think it will be a small-scale niche for at least a decade."

Losing GE fish

Many aquaculture scientists remain uneasy about the environmental risk to wild ecosystems if transgenic fish slip out of their farms. Although other agencies will presumably be involved in assessing risk as the projects advance, "the FDA has no in-house capacity to evaluate or understand the ecological consequences of transgenics in an aquatic ecosystem," says Conner Bailey, professor emeritus of rural sociology at Auburn University in Alabama. "And once you get anything into an aquatic ecosystem, it's really hard to control."

AquaBounty's protection scheme begins with multiple levels of physical barriers in its RAS facilities. Additionally, the salmon are all female and "triploid" (their DNA is in three rather than two sets of chromosomes) so they can't reproduce. However, scientists say neither of these measures can be 100 percent effective at preventing transgenic fish from escaping, disrupting local ecosystems, and potentially breeding in the wild.

More generally, while AquaBounty is committed to land-based systems, there are concerns that it's also creating far more GE eggs than it needs for its own production. Other industry groups, such as the Atlantic Salmon Federation, worry that other producers AquaBounty sells to might not be so careful, or that other companies around the world might move ahead with similar projects but without the same precautions. And all bets on risk are off if GE fish are raised in the ocean, where fish routinely escape, sometimes in large numbers.

Devlin's group has extensively modeled the results of accidental releases, studying groups of transgenic and non-transgenic fish in "naturalized" aquatic test beds that are exposed to variations in conditions, such as food supply. Transgenic fish often behave quite differently, and the results have varied from peaceful coexistence to one experiment in which fully transgenic fish killed off all their competitors.

"In the multitude of different environments that exist in nature, the uncertainty is too great to make a reliable prediction of what the impact would be," he says.

GE or selective breeding?

Does the fast growth of AquAdvantage salmon justify taking on these unknown risks? Scientists point out that today's selective breeding research programs, built on genomics and other tools of modern biology, also have turbocharged fish development. "Some strains of rainbow trout, which have been selected for fast growth for 150 years, grow incredibly fast compared to wild-type fish," Devlin says. In fact, he says, his lab work across various species suggests that "the absolute fastest growth you can achieve either by domestication or by transgenesis seems to be very similar."

"Today's farmed salmon have had more than 10 generations of selection applied to them, and they are growing at more than double the rate compared to the 1970s," says Bjarne Gjerde, senior scientist at Nofima in Troms, Norway.

Farmed fish also must excel in many traits besides growth, such as disease resistance and food quality, he emphasizes. "Most of the traits we are breeding for are governed by many, many genes with small effects," he says. "That's a real challenge if you just want to take short cuts with genetic engineering."

When and if AquaBounty rises above all its challenges into a groundbreaking success in North America, the firm will send a signal around the world to unleash efforts for commercializing GE fish, observers say. Friends of the Earth's Perls remains hopeful that legal barriers and consumer boycotts will stop AquaBounty in its tracks. If not, "GE salmon could set a precedent to the approval of other GE animals in the pipeline, from fish to chickens, pigs, and cows," she says. "It is critical that we don't approve other GE animals without robust regulations and full environmental reviews to ensure that we're prioritizing human and environmental safety over profit."

"Fish are probably where transgenic animals will emerge, because it's much cheaper to maintain a herd of catfish or salmon than cattle or sheep or pigs," says Bailey.

This story was first published by Ensia, an environmental news magazine from the University of Minnesota.

This article originally appeared at PRI's The World.

More here:

Genetically engineered salmon is coming to America - The Week Magazine

Are Pink Pineapples Safe to Eat? – Observer

While the FDA has approved the new genetically modifiedfruit made by Del Monte, there really isnt any data about its safety. Unsplash/Pineapple Supply Co

#PinkPineapples may beinfiltrating your Instagram feed, but just how safe are they?

The truth is, we dont know. While the FDA has approved the new genetically modifiedfruit made by Del Monte, there really isnt any data about its safetybeyond what the companytold the FDA. According to NBC, Del Monte submitted information to the agency to demonstrate that the pink flesh pineapple is as safe and nutritious as its conventional counterparts.

But what constitutes safe? How do we know that in 10 or 20 yearsor after some length of time consuming these genetically modified foodsit wont cause a problem?What we do know is that genetic engineering changes the DNA of plants and crops in orderto make them heartier, more resistant to infections and herbicides and able toyield larger amounts of food to feed more people. This, of course, on the surface, sounds promisinguntil you dig deeper.

Genetic engineering creates changes at a cellular level that cannot be easily seen or understood. These changes have the potential for substantial health implications. Take allergies, for instance. If genes from a highly-allergenic plant are transferred to another plant, the new plant now carries that allergenic potential. This happened in 1996, when a Brazil nut gene was added to soybeans in order to increase its nutritional status.The gene from the Brazil nut codes for a protein that causes allergic reactions in people with Brazil nut allergies. By adding this to the soy, a number of people experienced allergic reactions to something they werent otherwise allergic to.

In order for the FDA to approve a genetically modified food, the GMO food must be substantially equivalent to the non-GMO foods. In other words, when it comes to how our bodies process the foods, the two should be almost identical. However, a recent study showed that GMO corn was not substantially equivalent tonon-GMO corn, even though the FDA approved it as such. The GMO corncontained higher levels of several proteins that are known to be toxic to humans. In general, we are seeing an increase in GMO plants that have toxic genes created for specific purposes.

Many plants are now genetically modified to internallyproduce their own pesticides, protecting them from the insects that might damage them. Butwhen these GMO plants are used to feed animals, the animals are at increased risk for diseases. A 2012 study in Norway showed that rats fed a diet of GMO corn with pest resistancegot fatter than rats fed non-GMO corn. The lead professor on that study explained that the rats that had fed on GMO corn were slightly larger, they ate slightly more, their intestines had a different microstructure, they were less able to digest proteins, and there were some changes to their immune system. Blood samples also showed some change in the blood. Isnt it interesting that these rats developed exactly what we are seeing in the explodingepidemics of obesity, metabolic syndrome and chronic diseases in humans?

Another takeaway from that study contradicts a long-held belief about the safety of genetically modified food. Proponents of GMO claim that the new genes introduced into the genetically modified food are harmless and are digested and eliminated throughthe gastrointestinal tract. But the 2012 Norwegian study showed that these new genes could be transferred through the intestinal wall into the blood, and were found in the liver and even in muscle tissue. This implies that foreign genes could assimilate into our own DNA, turning on or off genes that have important functions. This could have far reaching effects on things like the development of cancer, changes in growth or longevity, and even the development of diseases like diabetes.

We are also seeing an increase in GMO plants bred with resistance to the herbicide glyphosate, or Round Updesigned to protect plants from the weed killer used to kill everything around it. But instead of helping farmers, this increased the weeds resistance to weed killer creating what is known as superweeds. As a result, farmers have had to dramatically increase the amount of pesticides used to control the situation, driving up food cost but also increasing the toxic levels of pesticides in our environment. In addition, plants that are resistant to glyphosate have grown out of control as well. For example, genetically modified canola is spreading uncontrollably throughout California.

Like any new invention or discovery, the initial benefits of genetic engineeringseem exciting and life changing. With time, it is becoming clear that we are just at the tip of the GMO iceberg and need to brace ourselves for what is yet to come. Until we know more about the long-term effects, I would strongly recommendavoiding genetically modified foods whenever possible. For my family, I chooseorganic fruits,vegetables,grass-fed/pastured meat and eggs and I urge the same for my patients and for you.

Dr.TaniaDempseyMD is an expert in chronic disease, autoimmune disorders and mast cell activation syndrome. Dr.Dempseyreceived her MD from The Johns Hopkins University School of Medicine and her BS degree from Cornell University. She completed herResidency at NYU Medical Center/ Bellevue Hospital and then served as an attending physician at a large multi-specialty medical practice in White Plains, NY, before opening Armonk Integrative Medicine. Dr.Dempseyis sought after internationally for her knowledge of chronic immune dysregulation and MCAS.For more information, please visitwww.drtaniadempsey.com

Visit link:

Are Pink Pineapples Safe to Eat? - Observer

FDA Moves On Novartis Gene Therapy May Be Good For Kite Pharma – Barron’s


Barron's
FDA Moves On Novartis Gene Therapy May Be Good For Kite Pharma
Barron's
A Food And Drug Administration panel is expected to meet tomorrow to discuss Novartis's (NVS) experimental gene therapy drug, a move that could be good news for Kite Pharma (KITE), according to Canaccord Genuity. Illustration: Getty Images/iStockphoto.
FDA Decision on Novartis Gene Therapy Drug Could Benefit Kite PharmaTheStreet.com

all 77 news articles »

Visit link:

FDA Moves On Novartis Gene Therapy May Be Good For Kite Pharma - Barron's

FDA panel to focus on safety of Novartis gene therapy drug – Reuters

(Reuters) - The U.S. Food and Drug Administration will ask a panel of advisors to focus on the safety of Novartis AG's experimental gene therapy drug when it meets to review the product on Wednesday.

The keenly anticipated preliminary review of the leukemia treatment, posted on the FDA's website on Monday, comes two days ahead of the advisory panel meeting, which will discuss the drug and vote on whether the benefits exceed the risks.

If approved, the drug, tisagenlecleucel, would be the first gene therapy to be approved in the United States. The FDA is not obliged to follow the recommendations of its advisors but typically does so.

The panel's decision could have significant implications not only for Novartis but for companies making similar drugs, including Kite Pharma Inc. Juno Therapeutics Inc and bluebird bio Inc.

The drugs use a new technology known as CAR-T, or chimeric antigen receptor T-cell therapy, which harnesses the body's own immune cells to recognize and attack malignant cells.

If approved they are expected to cost up to $500,000 and generate billions of dollars for their developers. Success would also help advance a cancer-fighting technique that scientists have been trying to perfect for decades.

Novartis is applying for approval in the first instance to treat B-cell acute lymphoblastic leukemia (ALL), the most common type of childhood cancer in the United States.

A clinical trial showed that 83 percent of patients who had relapsed or failed chemotherapy achieved complete or partial remission three months post infusion. Patients with ALL who fail chemotherapy typically have only a 16 to 30 percent chance of survival.

The FDA said it is not asking the panel to focus on whether the drug works, as it successfully met the main goal of the clinical trial. The panel will be asked only to focus on the short-term and long-term safety risks.

About half the patients experienced a serious complication known as cytokine release syndrome (CRS) which occurs when the body's immune system goes into overdrive. Doctors were able to manage the condition and it caused no patient deaths.

The FDA also raised concerns that the drug may cause secondary malignancies to occur and said long-term safety monitoring may be needed to address this concern.

Novartis is also testing its drug in diffuse large b-cell Lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, as is Kite. Part of the competitive landscape will include which company is best able to manufacture its drugs efficiently and reliably.

Reporting by Toni Clarke in Washington; Editing by Nick Zieminski

Originally posted here:

FDA panel to focus on safety of Novartis gene therapy drug - Reuters

Korea Approves the World’s First Cell and Gene Therapy for Knee Osteoarthritis – PR Newswire (press release)

Kolon Life Science filed for a Biologics License Application (BLA) for Invossa-K Inj. with MFDS in August 2016 based on efficacy results from its Phase III clinical trials conducted at 12 major university hospitals in Korea. Invossa-K Inj. will be manufactured by Kolon Life Science, and marketed by Mundipharma and Kolon Pharmaceuticals for the Korean market.

"We are excited to launch the world's first cell and gene therapy for knee osteoarthritis and potentially the world's first disease-modifying osteoarthritis drug (DMOAD)," stated Mr. Woosok Lee, CEO of TissueGene. "This approval is the first critical step towards a global launch for this innovative, novel cell and gene therapy technology that will address one of the most pressing unmet medical need affecting millions of people suffering from osteoarthritis worldwide."

Invossa is a first-in-class cell and gene therapy drug designed to conveniently and effectively treat osteoarthritis of the knee through a single intra-articular injection. Clinical trials completed in Korea and on-going in the US have demonstrated pain relief, increased mobility, and potentially game-changing improvements in joint structure offering substantial relief and convenience for osteoarthritis patients who would otherwise be in need of surgery.

Through its national US Phase III clinical trials, TissueGene will be using the results to seek a DMOAD designation for Invossa from the US Food and Drug Administration (FDA), potentially making Invossa the first and only cell and gene therapy for osteoarthritis of the knee.

In November last year, Kolon Life Science signed a license agreement with Mitsubishi Tanabe Pharmaceutical Corporation, and Mitsubishi Tanabe Pharma is proceeding with the preparation of clinical trials through its exclusive development and commercialization rights in Japan.

TissueGene, Inc. TissueGene, Inc., is a Maryland-based regenerative medicine company specializing in cell and gene therapy. TissueGene's lead product is Invossa, an allogeneic, cell and gene therapy for osteoarthritis of the knee that is preparing for Phase III clinical trials in the US pursuant to a Special Protocol Assessment (SPA) agreement reached with the U.S. Food and Drug Administration. Information about the trials can be found at the NIH registry, ww.clinicaltrials.gov. For additional information about TissueGene, Inc., please visit http://www.tissuegene.com.

Kolon Life Science Kolon Life Science has been developing innovative cell and gene therapies including Invossa K Inj., the world's first cell-mediated gene therapy for osteoarthritis, since its founding in 2000. In addition to its biopharmaceuticals business, the company is also engaged in the business of providing active pharmaceuticals ingredients (API), eco-chemicals including antimicrobials for personal-care and industrial applications, as well as water-treatment solutions. For more information, please visit http://www.kolonls.co.kr/eng

View original content:http://www.prnewswire.com/news-releases/korea-approves-the-worlds-first-cell-and-gene-therapy-for-knee-osteoarthritis-300486969.html

SOURCE TissueGene, Inc.

See the rest here:

Korea Approves the World's First Cell and Gene Therapy for Knee Osteoarthritis - PR Newswire (press release)

Breathing in a New Gene Therapy to Treat Pulmonary Hypertension – Newswise (press release)

Breathing in a New Gene Therapy to treat Pulmonary Hypertension

Newswise (New York, NY July 12, 2017) Mount Sinai has partnered with Theragene Pharmaceuticals, Inc. to advance a novel airway-delivered gene therapy for treating pulmonary hypertension (PH), a form of high blood pressure in blood vessels in the lungs that is linked to heart failure. If the therapy succeeds in human clinical trials, it will provide patients for the first time with a way to reverse the damage caused by PH.

This gene therapy technique comes from the research of Roger J. Hajjar, MD, Professor of Medicine and Director of the Cardiovascular Research Center at the Icahn School of Medicine at Mount Sinai, and has been proven effective in rodent and pig animal models. PH is a deadly disease that disproportionately affects young adults and women; 58 percent of cases are found in young adults and 72 percent are women. There is currently no effective cure for PH, and about 50 percent of people who are diagnosed will die from the disease within five years.

PH is a rare (15-50 cases per million people), rapidly progressing disease that occurs when blood pressure is too high in vessels leading from the heart to the lungs. The high pressure is caused by abnormal remodeling of the lung blood vessels, characterized by a proliferation of smooth muscle cells and a thickening and narrowing of these vessels, and can lead to failure of the right ventricle of the heart and premature death. Abnormalities in calcium cycling within the vascular cells play a key role in the pathophysiology of pulmonary hypertension, along with deficiencies in the sarcoplasmic reticulum calcium ATPase pump (SERCA2a) protein which regulates intracellular calcium within these vascular cells and prevents them from proliferating within the vessel wall. Downregulation of SERCA2a leads to the proliferative remodeling of the vasculature. This gene therapy, delivered via an inhaled aerosolized spray, aims to increase the expression of SERCA2a protein, and has been shown in rodents and pigs to improve heart and lung function, as well as reduce and even reverse cellular changes caused by PH.

This is a devastating disease, and our work in collaboration with many laboratories across the country has allowed us to identify a specific molecular target and use gene therapy to improve cardiovascular and lung parameters in experimental models of PH. We look forward to starting first-in-human studies using this approach in affected patients, said Dr. Hajjar, the senior author of the studies, highlighting that clinical trials will be underway in the next two years.It may take several years before a product is commercially available for PH patients.

We are excited about the potential for SERCA2a gene therapy as a new modality in treating this serious disease, said Jon Berglin, Chief Executive Officer of Theragene Pharmaceuticals, Inc. We look forward to develop and advance this promising product into the clinic.

This represents another critical advancement in a potentially transformative therapeutic breakthrough by Mount Sinai scientists, demonstrating our commitment to improving health outcomes. We are thrilled to be working with Theragene Pharmaceuticals, and continue to strengthen our expertise in partnering health care innovations with industry, said Erik Lium, PhD, Senior Vice President of Mount Sinai Innovation Partners, the commercialization arm of the Icahn School of Medicine at Mount Sinai.

About Mount Sinai Innovation Partners (MSIP)MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships with industry. The aim is to translate these innovations into healthcare products and services that benefit patients and society. MSIP is responsible for the full spectrum of commercialization activities required to bring the Icahn School of Medicine and the Mount Sinai Health Systems inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies, engaging commercial and non-profit relationships for sponsored research, material transfer and confidentiality, as well as fostering an ecosystem of entrepreneurship within our research and health system communities. For more information, visit http://www.ip.mountsinai.org.

About Theragene Pharmaceuticals, Inc.Theragene is a biopharmaceutical company developing cutting-edge science for the treatment of debilitating diseases. The Companys diverse portfolio consists of preclinical and clinical oncology and cardiology platforms utilizing next generation gene therapy and immunotherapy methods.

See the article here:

Breathing in a New Gene Therapy to Treat Pulmonary Hypertension - Newswise (press release)

This Wearable MRI Device Could Help Us Read Minds – Futurism

In Brief Mary Lou Jepsen, former head of display technology at Oculus, has founded a startup called Openwater that hopes "to create a wearable to enable us to see the inner workings of the body and brain at high resolution." A Wearable MRI

What if you couldseedirectly into another persons brain? Theability to read minds, referred to as telepathy, is yet another concept thatsabundant in science fiction, but a former Facebook executive says that we could all be capable of at least seeing inside someone elsesmind provided that were equipped with the right technology.

Mary Lou Jepsen was the head of display technology at Oculus before founding her own startup called Openwater. The companys goal, while ambitious, is in theory quite simple: to create a wearable to enable us to see the inner workings of the body and brain at high resolution. In short, telepathy courtesy of a brain-computer interface (BCI) a wearable device that works like an Magnetic Resonance Imaging (MRI) machine.

I dont think this is going to take decades, Jepsen said of the techs development, during an interview withCNBC. I think were talking about less than a decade, probably eight years until telepathy. Her company plans to make avery limited number of prototypes available to their early access partners by next year.

Wearable MRI technology could be quite an asset in terms ofdisease diagnosis and treatment. With just one quick look, a physician couldsee whats happening inside a persons brain, or elsewherein the body.Of course, this raises many questions and concerns about privacy, which Jepsen says the company is working on. Were trying to make the hat only work if the individual wants it to work, and then filtering out parts that the person wearing it doesnt feel its appropriate to share, she said.

Openwater isnt the only one working to give the human brain machine-like capabilities. In fact, Facebook is also developing a device similar to Jepsens. BCIs, which already haveapplications in prosthesis use, could also become apopular means to prepare humankind for future of intelligent machines.

This is whatTesla and SpaceX CEO Elon Musk has in mind withhis mind/machine merging venture, Neuralink. The U.S. Department of Defenses research arm,DARPA, is also working on projects that would combinehumans with machines. Another company is Kernel, which has been working on a neuroprosthesis that can make the brains neural code programmable.

Disclosure: Bryan Johnson is an investor in Futurism; he does not hold a seat on our editorial board or have any editorial review privileges.

Read more:

This Wearable MRI Device Could Help Us Read Minds - Futurism

Humanity Is About to Transition To Evolution by Intelligent Direction – Futurism

Disclaimer: Futurism only supports products that we trust and use. This post is in partnership with Abundance 360, and Futurism may get a small percentage of sales. Want to take a class with Peter Diamandis? Click here to learn more! Reinventing Humanity

As we close out 2016, if youll allow me, Id like to take a risk and venture into a topic Im personally compelled to think about, a topic that will seem far-out to most readers.

Todays extraordinary rate of exponential growth may do much more than just disrupt industries. It may actually give birth to a new species reinventing humanity over the next 30 years.

I believe were rapidly heading towards a human-scale transformation, the next evolutionary step into what I call a meta-intelligence, a future in which we are all highly connected brain to brain via the cloud sharing thoughts, knowledge, and actions.

In this blog, Im investigating the driving forces behind such an evolutionary step, the historical pattern we are about to repeat, and the implications thereof. Again, I acknowledge that this topic seems far-out, but the forces at play are huge and the implications are vast.

Lets dive in

About 4.6 billion years ago, our solar system, the Sun, and the Earth were formed. Four steps followed

Today, at a massively accelerated rate some 100 million times faster than the steps I outlined above life is undergoing a similar evolution. In this next stage of evolution, we are going from evolution by natural selection (Darwinism) to evolution by intelligent direction.

Allow me to draw the analogy for you:

Four primary driving forces are leading us towards our transformation of humanity into a meta-intelligence both on and off the Earth:

Lets take a look at each.

Today, there are 2.9 billion people connected online. Within the next six to eight years, that number is expected to increase to nearly 8 billion, with each individual on the planet having access to a megabit-per-second connection or better.

The wiring is taking place through the deployment of 5G on the ground, plus networks being deployed by Facebook, Google, Qualcomm, Samsung, Virgin, SpaceX, and many others.

Within a decade, every single human on the planet will have access to multimegabit connectivity, the worlds information, and massive computational power on the cloud.

A multitude of labs and entrepreneurs are working to create lasting, high-bandwidth connections between the digital world and the human neocortex (I wrote about that in detail).

Ray Kurzweil predicts well see human-cloud connection by the mid-2030s, just 18 years from now.

In addition, entrepreneurs like Bryan Johnson (and his company Kernel) are committing hundreds of millions of dollars towards this vision.

The end results of connecting your neocortex with the cloud are twofold: First, youll have the ability to increase your memory capacity and/or cognitive function millions of fold; second, via a global mesh network, youll have the ability to connect your brain to anyone elses brain and to emerging AIs, just like our cell phones, servers, watches, cars, and all devices are becoming connected via the Internet of Things (IoT).

Next, and perhaps most significantly, we are on the cusp of an AI revolution.

Artificial intelligence, powered by deep learning and funded by companies such as Google, Facebook, IBM, Samsung, and Alibaba, will continue to rapidly accelerate and drive breakthroughs.

Cumulative intelligence (both artificial and human) is the single greatest predictor of success for both a company or a nation. For this reason, beside the emerging AI arms race, we will soon see a race focused on increasing overall human intelligence.

Whatever challenges we might have in creating a vibrant brain-computer interface (e.g. designing long-term biocompatible sensors or nanobots that interface with your neocortex), those challenges will fall quickly over the next couple of decades as AI power tools give us every increasing problem-solving capability.

It is an exponential atop an exponential. More intelligence gives us the tools to solve connectivity and mesh problems and in turn create greater intelligence.

Finally, its important to note that the human race is on the verge of becoming a multiplanetary species.

Thousands of years from now, whatever weve evolved into, we will look back at these next few decades as the moment in time that the human race moved off Earth irreversibly.

Today, billions of dollars are being invested privately into the commercial space industry. Efforts led by SpaceX are targeting humans on Mars, while efforts by Blue Origin are looking at taking humanity back to the Moon and plans by my own company, Planetary Resources, strive to unlock near-infinite resources from the asteroids.

The rate of human evolution is accelerating as we transition from the slow and random process of Darwinian natural selection to a hyper-accelerated and precisely directed period of evolution by intelligent direction.

In this blog, I chose not to discuss the power being unleashed by such gene-editing techniques as CRISPR-Cas9. Consider this yet another tool able to accelerate evolution by our own hand.

The bottom line is that change is coming, faster than ever considered possible. All of us leaders, entrepreneurs, and parents have a huge responsibility to inspire and guide the transformation of humanity on and off the Earth.

What we do over the next 30 years the bridges we build to abundance will impact the future of the human race for millennia to come. We truly live during the most exciting time ever in human history.

Disclaimer: Futurism only supports products that we trust and use. This post is in partnership with Abundance 360, and Futurism may get a small percentage of sales. Want to take a class with Peter Diamandis?Click here to learn more!

Visit link:

Humanity Is About to Transition To Evolution by Intelligent Direction - Futurism

House Freedom Caucus to Air Debt Ceiling Demands – Roll Call

The House Freedom Caucus plans to lay out three ways members would support raising the debt ceiling this month, including overhauling the debt limit and payment system or making deep cuts to mandatory spending.

The roughly 40-member group of hard-line conservatives will ask GOP leaders to raise the debt ceiling in July alongside other legislative provisions to win their support, as first reported by Axios and confirmed by CQ Roll Call.

One option is a bill from Freedom Caucus member David Schweikert, R-Ariz., that would call on the Treasury Department to rescind unobligated federal funds from agencies; sell off certain government assets; and issue bonds linked to gross domestic product, to pay down the public debt when Treasury estimates the debt limit will soon be reached.

The legislation was introduced by Schweikert last week and lists Freedom Caucus Chairman Mark Meadows, R-N.C., as a co-sponsor.

Congress needs to suspend or raise the debt limit by early-to-mid October, according to recent estimates from the nonpartisan Congressional Budget Office.

Top lawmakers like Sen. John Cornyn of Texas, the Republican whip, have said they want to address the debt ceiling before the August recess but a concrete plan for doing so has yet to emerge.

House Majority Leader Kevin McCarthy of California declined to set a similar deadline for his chamber. He said that the House will wait to take up a debt limit vote until after Congress repeals and replaces the 2010 health care law.

I want to get it done in advance, but there is no set [decision] that we have to do it in July, McCarthy said before the Independence Day recess.

I think health is going to have to get done first, he continued.

The debt limit suspension expired on March 15 and since then, the Treasury Department has been using extraordinary measures to continue paying the nations bills.

Other options the Freedom Caucus will propose are tagging the debt limit increase to $250 billion in mandatory spending cuts over an unspecified time period or a full repeal of the 2010 health care law, a Freedom Caucus aide confirmed.

The three options are highly ambitious and would face certain resistance in the Senate if passed by the House.

Get breaking news alerts and more from Roll Call on your iPhone or your Android.

Visit link:

House Freedom Caucus to Air Debt Ceiling Demands - Roll Call

Superhero Night, fireworks kick off weekend of promos as Freedom return from All-Star break Friday – User-generated content (press release)…

The first-place Florence Freedom, presented by Titan Mechanical Solutions, return from the Frontier League All-Star Break with a weekend home series at UC Health Stadium, Friday through Sunday.

The weekend is filled with promotions for the series against the Normal Cornbelters, beginning Friday with Superhero Night and fireworks.

FRIDAY, JULY 14 SUPERHERO NIGHT AND FIREWORKS (GAME TIME 7:05 PM)

Superheroes from the DC Comics collection, including Superman, Batman and The Flash, will be at the ballpark available for photos and interactions with fans throughout the evening. There will also be a Girl Scouts campout on the field after the game.

Additionally, Elite Pyrotechnics will once again put on a spectacular post-game fireworks show, presented by Arlinghaus Heating and Air Conditioning.

SATURDAY, JULY 15 MARTIAL ARTS NIGHT AND POSTGAME CONCERT (6:05 PM)

The team will wear special Freedom Ranger jerseys that will be auctioned off after the game. Mike Dominach will also lead a Taekwondo lesson on the field post-game.

Also after the game, the Freedoms Kerry Toyota Rockin Saturday series continues with a post-game concert by What She Said, presented by Hudy Delight. During the concert, kids 12 and under can participate in a game of kickball on the field, supervised by Freedom interns.

SUNDAY, JULY 16 YOUTH SPORTS DAY AND FAMILY SUNDAY (6:05 PM)

The Freedom will celebrate all local youth sports teams and organizations by giving back 30% of all ticket sales for the evening to family, friends and neighbors.

Kids will be able to run the bases after the game, and as the kids come off the field, they will be greeted by the entire Freedom team for a post-game autograph session presented by Cornerstone Lillie Insurance.

The Florence Freedom are members of the independent Frontier League and play all home games at UC Health Stadium located at 7950 Freedom Way in Florence, KY.The Freedom can be found online at FlorenceFreedom.com, or by phone at 859-594-4487.

Florence Freedom

Read the original:

Superhero Night, fireworks kick off weekend of promos as Freedom return from All-Star break Friday - User-generated content (press release)...

WWII veterans recall memories during Wings of Freedom Tour in Billings – KTVQ Billings News

BILLINGS -

History took to the skies over Billings on Tuesdayas the "Wings of Freedom Tour" entertained from the sky and tarmac.

Theevent honors veterans of World War II and featuresvintageaircraft that requires upkeep 365 days a year..

The tour provided an experience to ride inand even take lessons in operating aircraft over 70 years old.

The experience was unbelievable," said Steve Olson, who is the nephew of a WWII tech sergeant. "My Uncle Fred worked on the B-17s over in England, he flew across the pond in it. I cannot imagine, but he did it and he loved it. Ive been living the memory ever since.

Fred Groff, who was alongside Olson for the tour,recalled the experience of repairing combat damaged aircraft.

Wed get them back in about a day and ready to start bombing again," Groff said.So it had to be an atomic bomb, that was small enough to put in those, and they thought that it would start exploding, they thought that it possibly go around the earth, and destroy all of our Earth.

The experience of standing next to the aircraft in which they defended our countrys freedom proved to be emotional for some.

It was such a treat to be able to fly for him today. Even at my old age, its pretty cool to be able to do something like that with him," Olson said.

Sights and sounds that most of us can only imagine, from history books, and movies.

Twice, I almost had to jump, because I came off the bomb run, and Im the nose, and I was looking straight at the ground. When I went in it, I remembered it all, said Kenneth Hall, a WWII gunner.

Families got to witness the camaraderie rekindled by the tour -- machineryand memories from a long time ago.

Its kinda nice that theyre still up and moving around arent they?

Yeah, its kinda nice that we are too.

For many, they are experiencing these planes as flying museums. But for a handful of men, it has been a trip down memory lane.

That was some ride, Hall said.

Read more:

WWII veterans recall memories during Wings of Freedom Tour in Billings - KTVQ Billings News

Ask SAM: Is NC First in Freedom? Flight? Anything else? | Ask SAM … – Winston-Salem Journal

Q: Many years ago, there was a controversy over whether North Carolina could be called First in Freedom on license tags. The N.C. Division of Motor Vehicles also issued auto license plates with First in Flight which were challenged by Ohio. After all these years of that, I now see that new license plates are back to First in Freedom. What other firsts can North Carolina claim?

Answer: According to the state Department of Transportation, the First in Freedom plate recognizes two events: The signing of the Mecklenburg Declaration of Independence on May 20, 1775, and the Halifax Resolves on April 12, 1776.

These two events are also commemorated on the North Carolina state flag, according to the DOT, and are regarded as the first steps toward independence from Great Britain during the early stages of the American Revolution.

You can read more about the Mecklenburg Declaration at the Mecklenburg Historical Associations website, http://www.meckdec.org/declaration. Bear in mind that some historians dispute the authenticity of that declaration. Also, there has been some controversy about how appropriate the slogan First in Freedom is for a state that allowed slavery for so long.

First in Freedom plates were reinstated as an option in 2015. At the time, Gov. Pat McCrory said North Carolina is a state of firsts and we continue to be a leader in innovation. What a great way to celebrate North Carolinas rich history and the birth of our nation by offering drivers a chance to proudly display a plate that honors our contribution to freedom, here in one of the most military friendly states.

As to First in Flight, the dispute there is over which state should get credit for the flight of Wilbur and Orville Wright, who were from Ohio but made their historic flight in North Carolina. According to NCPedia.org, Wilbur was gathering information about flight and wrote to the United States Weather Bureau to learn about wind speeds in different places around the country to find the most favorable conditions.

The Weather Bureau told Wilbur about Kitty Hawk on the Outer Banks. Wilbur then wrote the Kitty Hawk weather station to ask about the area. He received a warm reply from the local postmaster, Bill Tate. Kitty Hawk had more to offer than just strong winds, Tate told Wilbur. It also had soft sand for landing a glider and friendly people who would be willing to help. And it was an isolated place where Wilbur could get the privacy he wanted.

The brothers traveled back and forth between their bicycle shop in Dayton, Ohio, and Kitty Hawk while working on the project.

Connecticut also claims to be first in flight, citing a powered flight by Gustave Whitehead there in 1901, two years before the Wright Brothers flight in 1903.

As to other firsts, according to the Secretary of States office, we can claim the first public university in the United States (UNC Chapel Hill), the first English child born in America (Virginia Dare), the first state art museum, the first outdoor drama in America (The Lost Colony), Americas first gold rush, and the first known miniature golf course, which is neat but probably not good fodder for a license plate slogan.

Link:

Ask SAM: Is NC First in Freedom? Flight? Anything else? | Ask SAM ... - Winston-Salem Journal

Know the dark side of North Carolina eugenics – The Daily Tar Heel

Claude Wilson | Published 13 hours ago

Alongside the benefits of our growing understandingof genetics, theres been the dark shadow of its pseudoscience.

More than just an unfortunate chapter of history confined to Nazi Germany, eugenics the practice of selective breeding has long had a foot in American politics. North Carolina provides a perfect example of the wretched history of eugenics in the United States.

The focal point of the Old North States relationship with eugenics over the years was the Eugenics Board of North Carolina, a state board formed in 1933. It forcibly sterilized citizens, many of whom were black and impoverished.

The stated targets of sterilization of the Eugenics Board were the so-called feeble-minded, which was bad enough, but they also sterilized the blind and deaf, expanding to the sterilization of any welfare recipients social workers chose to single out. Over the course of more than 40 years, about 7,600 people were sterilized by the state until 1977, when the Eugenics Board was formally abolished. However, laws allowing involuntary sterilization remained in place until as late as 2003.

The driving force behind the forced sterilizations authorized by the Eugenics Board after World War II was the so-called Human Betterment League, an organization made up of Winston-Salems wealthy elite for the purpose of furthering the cause of eugenics in North Carolina. Founded in 1947, the efforts of the League led to an 80 percent increase in forced sterilizations in the state and continued to promote forced sterilizations until the early 1970s, eventually disbanding in 1988.

Beyond thousands of forced sterilizations administered under the authority of the Eugenics Board, countless more were carried out by local clinics in the state. While a bill passed in 2013 provided compensation to victims of involuntary sterilization by the Eugenics Board, no compensation has been instituted for victims of these clinics.

North Carolina is only one of many states that have sanctioned forced sterilization. Beyond the already horrible history of American eugenics, the American model of eugenics and forced sterilization would provide a direct model for similar programs implemented in Nazi Germany.

Harry Laughlin, one of the leading American eugenicists of the 1930s, would brag to colleagues about how Nazi Germany was adapting his compulsory sterilization law models, and in 1936 was awarded an honorary degree by the University ofHeidelberg for his contributions to the science of racial cleansing.

Despite the repeated debunking of eugenics by respectable academics and researchers, Social Darwinist thinking and support for eugenicist thought remainfar more prevalent than they should. The most prominent example is Richard Herrnstein and Charles Murrays1994 "The Bell Curve," a perniciously ignorant, poorly researched and deliberately misleading book which claims human intelligence is linked to race. The book was published without any peer review, based itself on flawed statistical methods and faulty assumptions and has been torn to shreds by a number of prominent scholars.

But Charles Murrays pseudo-research is still taken seriously in certain circles. The majority of Murrays research came from the Pioneer Fund, a non-profit foundation that has funded prominent white supremacists, such as Roger Pearson and Jared Taylor. Among the founding members of the fund was Harry Laughlin.

The original eugenicists saw themselves as philanthropists who were helping the world, and future neo-eugenicists will probably view themselves that way as well. This is why it is important we dispel the pseudoscientific, white supremacist myths that are perpetuated by people like Charles Murray and organizations like the Pioneer Fund.

opinion@dailytarheel.com

Read more in Opinion,

Share on social media?

See more here:

Know the dark side of North Carolina eugenics - The Daily Tar Heel

Library Board Delays Decision on Renaming Fisher Award – Seven Days

Famed Vermont author Dorothy Canfield Fisher's name will stay on a children's book award at least for now.

The Vermont Library Board met Tuesday and heard two and a half hours of debate about a request to rename the award. Critics behind the effort say Fisher was associated with the Vermont Eugenics Survey, and that she stereotyped its targets including French Canadians and French Indians in her writing.

But after several speakers at the meeting mounted a fierce defense of Fisher, the board delayed making a recommendation on whether to rename the award until its next meeting on October 10. State Librarian Scott Murphy will have the final say.

"I'm not trying to kick the can down the road, I'm trying to figure out a way to deal with this," board chair Bruce Post told Seven Days after the meeting in Berlin.*

Afterwards, he said he needed more time to consider the issue. "It's too early to comment. I have to internalize all that information," he said of the "really good commentary" he heard at the meeting.

Writer, artist and plumber Tom Mulholland of Montpelier attended to defend Fisher. He sat at the same table as Essex Junction resident Judy Dow, a French-Indian educator who is leading the push to remove Fisher's name from the award.

Mulholland accused Dow of historical "vandalism" and said her characterization of Fisher as a eugenicist was based on innuendo and insinuation. "Unless there's absolute fact, she's innocent," Mulholland said.

Retired University of Vermont professor Helene Lang also defended Fisher in a lengthy presentation to the board, calling criticism of the author "very unfair and inadequately substantiated."

She added: "I've lost sleep over this."

Both Lang and Mulholland noted that several prominent Vermonters served with Fisher on the Vermont Commission on Country Life, which grew out of the Vermont Eugenics Survey directed by UVM professor Henry Perkins.

Fisher's participation on the commission does not mean she supported the eugenics survey work, her defenders said.

Dow, though, said that the time has come to listen to those who have been oppressed and to consider changing the name on the award.

As Lang and Dow repeatedly engaged in sharp exchanges, Post eventually stepped in. "OK hold it," he said at one point. "Please stop."

Although none of the board members took a public stance at the meeting, several thanked Dow for bringing up the issue, saying it was a worthy debate.

*Clarification, 9:12 p.m.: A previous version of this story misstated when Post spoke to Seven Days.

View post:

Library Board Delays Decision on Renaming Fisher Award - Seven Days

Voices: Will we become cyborg Christians? – Baptist Standard

July 12, 2017 By James Hassell

I spent gobs of time sitting in airports recently. If you can believe it, I made it through a security line at Atlanta Hartsfield within 15 minutes. I think thats a new record for me.

James Hassell

Trying to kill time in an airport can be taxing, so I decided to peruse a noticeably thin copy of The Wall Street Journal. The headlines were what you would expect in just about any newspaper today. Nearly every story had to do with money, sex and/or power.

Then I noticed an incredible, half-page advertisement sponsored by an economic development organization called Enterprise Florida. The headline of the ad read: The Future of Everything: Erasing the Line Between Human and Machine. An especially thought-provoking line from the ad says, The future of the mind, from mental health to cognition, is a fusion of mind and machine.

I hope such an ad would get your theological mind spinning as it did mine. Are we really moving toward a time when the future of business and daily life consists of the fusion between people and machines? And if so, what does this mean for the church?

I dont know about you, but I really have no interest in becoming a cyborg pastor, although the thought is a rather unique one to consider. It seems with all of our technological progress, many still seek eternal life without Jesus Christ. Permanent and perfect transformation comes through Christ and Christ alone.

Lets be reminded of the Apostle Pauls great admonishment to us in Romans 12: Do not be conformed to this world, but be transformed by the renewing of your mind, so that you may prove what the will of God is, that which is good and acceptable and perfect.

It also may be of great interest to know fine ethical minds among Texas Baptists already are considering this nearly front-page contemporary issue. Jeph Holloway, professor at East Texas Baptist University, presented some highly valuable lectures regarding this topic at the annual T.B. Maston Christian Ethics Lectures at Logsdon Seminary. To see the lectures on YouTube, click here.

Please take a few moments to think deeply about the rise of man-machine, for this issue is one that will impact us and our churches significantly in the next decade.

James Hassell is senior pastor of First Baptist Church in San Angelo, Texas.

See the rest here:

Voices: Will we become cyborg Christians? - Baptist Standard